

### Key Indices Update

Indices	Close	Change (%)
Nifty	22337.30	1.15 ↗
Sensex	73730.23	1.01 ↗
Midcap	49168.35	2.42 ↗
Smallcap	15199.10	2.96 ↗

### Trend Strength Indicator

Nifty 50 Stocks above 200 EMA	NSE Advance / Decline
12	2461/436

### Key Data

Data	Current	Previous
Dow Jones	42,981.5	42,764.5
U.S. Dollar Index	104.15	105.71
Brent Crude (USD/BBL)	69.74	70.93
US 10Y Bond Yield (%)	4.31	4.26
India 10Y Bond Yield (%)	6.77	6.77

### Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	48506.15	0.54 ↗
NIFTYAUTO	20799	2.61 ↗
NIFTYENERGY	31107.4	2.87 ↗
NIFTYFINSRV	24695.65	0.53 ↗
NIFTYFMCG	51477.9	1.89 ↗
NIFTYIT	38063.15	2.11 ↗
NIFTYMEDIA	1445.4	2.95 ↗
NIFTYMETAL	8683.55	4.02 ↗
NIFTYPHARMA	20090.3	1.36 ↗
NIFTYREALTY	827	2.26 ↗

## Fundamental

Refer Page 02

### Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
ITC	FMCG	409	548	33.9%

\*CMP as on Mar. 05, 2025

### Top News

- ✦ **Wipro Limited** has launched **TelcoAI360** to **transform operations** for **telcos** by leveraging **AI**. The **AI-first Managed Services platform** will empower **telcos** to **roll out differentiated technology solutions** at **scale and speed**, while delivering **better customer experience** at a **fraction of the cost**.
- ✦ **Zydus Lifesciences** received **USFDA approval** to manufacture **Dasatinib Tablets**. This product treats **specific leukemia types**, with **2025 US sales** projected at **\$1807.7mn**.

## Technical

Refer Page 03-04

- ✦ **Nifty** saw a **much-needed rebound**, **gaining over a percent** amid mixed cues.
- ✦ **All key sectors participated** in the rally, with **metal, energy, and auto** emerging as the **top gainers**.
- ✦ Traders should **avoid reading too much** into a **single-day bounce** and **wait for further confirmation**.
- ✦ Nifty may **face resistance** around the **22,500-22,700 zone** if the **recovery continues**.
- ✦ **Stock of the day - INDHOTEL.**

# Fundamental

## Top News

- 01** **Wipro Limited** has launched **TelcoAI360** to **transform operations** for **telcos** by leveraging **AI**. The **AI-first Managed Services platform** will empower **telcos** to **roll out differentiated technology solutions** at **scale and speed**, while delivering **better customer experience** at a **fraction of the cost**.
- 02** **Zydus Lifesciences** received **USFDA approval** to manufacture **Dasatinib Tablets**. This product treats **specific leukemia types**, with **2025 US sales** projected at **\$1807.7mn**.
- 03** **TCS** partners with **Vantage Towers** to launch a **digital platform** transforming **property leasing** for **telecom towers** in **Europe**. Using **TCS Crystallus™ for Telecom**, this will **streamline services**, **strengthen site partnerships**, and drive **sustainable telecom expansion**.
- 04** **Galaxy Surfactants Limited** is collaborating with a **global customer** to provide **EPC services** for a **Performance Surfactants and Specialty Ingredients Plant overseas**. They're also in talks to **expand this partnership** post-commissioning, aligning with their **growth vision**.
- 05** **R Systems** launched an **IoT Smart C2C Connector** on **AWS**, enhancing **smart home device integration** with **secure, efficient connectivity solutions**.

Stock		ITC Ltd
Stock Symbol	ITC	<ul style="list-style-type: none"> <li>✦ <b>ITC is a diversified FMCG company having</b> strong presence in <b>Cigarettes, Hotels, Paperboards</b> and <b>Packaging, Agri Business</b> and <b>Information Technology</b> segments.</li> </ul>
Sector	FMCG	<ul style="list-style-type: none"> <li>✦ With a robust brand portfolio and <b>widespread market reach</b>, ITC effectively <b>mitigates risk through diversification</b>, capitalizing on brand equity to <b>capture market share</b> and <b>support sustained revenue</b>, thus reinforcing its leadership position.</li> </ul>
*CMP (₹)	409	<ul style="list-style-type: none"> <li>✦ Company is <b>launching new products</b> across multiple categories and <b>expanding distribution</b>, ITC is strengthening its core businesses. With a robust brand portfolio and widespread market reach, ITC effectively mitigates risk through diversification, <b>capitalizing on brand equity to capture market share and support sustained revenue</b>, thus reinforcing its leadership position</li> </ul>
^Target Price (₹)	548	<ul style="list-style-type: none"> <li>✦ Overall, we expect <b>growth</b> to be <b>continuously driven by cigarettes, FMCG and Value added agri product segments</b>.</li> </ul>
Upside	33.9%	<ul style="list-style-type: none"> <li>✦ On the financial front, we have estimated its revenue/ EBITDA/PAT to grow at 6.5%/5.8%/6.1% CAGR over FY24-27E and maintain <b>Buy rating</b> and a target price of <b>Rs 548</b>.</li> </ul>

\*CMP as on Mar. 05, 2025

^Time horizon - upto 11 Months


# Technical

**Recovery expected. Stay focused on stock selection.**

NIFTY
22337.30 <span style="color: green;">▲</span> 254.65 (1.15%)

S1	S2	R1	R2
21240	22100	22520	22630

Technical Chart : Weekly



- ✦ Nifty saw a much-needed rebound, gaining over a percent amid mixed cues.
- ✦ All key sectors participated in the rally, with metal, energy, and auto emerging as the top gainers.
- ✦ Traders should avoid reading too much into a single-day bounce and wait for further confirmation.
- ✦ Nifty may face resistance around the 22,500–22,700 zone if the recovery continues.
- ✦ We maintain a stock-specific approach, favoring banking, financials, and metals for long trades while remaining selective in other sectors.

BANKNIFTY
48489.95 <span style="color: green;">▲</span> 244.75 (0.51%)

S1	S2	R1	R2
48200	47900	48700	49000

Technical Chart : Weekly




- ✦ The banking index extended rebound and gained nearly half a percent.
- ✦ PSU banking stocks outperformed the private banking majors and gained over 2–3%. Hdfcbank and Indusindbk were laggards.
- ✦ The index has bounced from its support zone, however, the recovery remains fragile. The current structure suggests a sideways tone in the banking index.
- ✦ The immediate support lies at 48200–47900, while it may face resistance around 48700–49000 levels.

Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
<b>INDHOTEL</b>	<b>BUY</b>	757.20	755-758	732	810

Technical Chart : Daily



- ✦ **Indhotel** has **maintained** its **steady uptrend since inception**, demonstrating a **bullish structure**.
- ✦ However, **in line with market corrective phase**, the **stock too witnessed profit booking from record high levels**.
- ✦ It **retraced to the support of long term moving average and formed a base** after a couple of **weeks of consolidation**.
- ✦ The stock has **regained strength to revert towards its primary trend** on the back of **notable price action**, giving an **opportunity to go long**.

Momentum Stocks Midcap	Name	Price	Price %
	IIFL	315.1	11.11 ↗
	REDINGTON	247.6	8.34 ↗
	DEEPAKFERT	1050	7.60 ↗
	SONACOMS	509.9	7.53 ↗
	QUESS	631.9	7.49 ↗

Name	Price	Price %	Range Breakout/ Breakdown
JSWENERGY	508.95	5.76 ↗	
GMRINFRA	74.36	4.44 ↗	
LAURUSLABS	566.95	3.93 ↗	
CESC	141	2.93 ↗	
HINDALCO	657.35	2.45 ↗	

Top 5 F&O Gainers ↗	Name	Price	Price %
	IIFL	313.70	10.61 ↗
	ADANIGREEN	848.70	10.43 ↗
	ADANIENSOL	709.45	9.71 ↗
	COFORGE	7,814.20	8.34 ↗
	ATGL	589.90	7.81 ↗

Name	Price	Price %	Top 5 F&O Losers ↘
BSE	4,299.10	3.47 ↘	
BAJFINANCE	8,298.70	3.35 ↘	
INDUSINDBK	971.85	1.59 ↘	
VOLTAS	1,387.80	1.54 ↘	
MUTHOOTFIN	2,125.90	1.20 ↘	

Bullish Charts	Name	Price	Price %
	INDHOTEL	757.20	5.62 ↗
	JSWENERGY	509.10	5.79 ↗
	NTPC	326.20	3.97 ↗
	PFC	395.75	3.25 ↗
	TATASTEEL	146.10	4.85 ↗

Name	Price	Price %	Bearish Charts
BALKRISIND	2,498.00	1.14 ↘	
COLPAL	2,409.65	0.82 ↘	
GODREJCP	991.35	0.11 ↘	
MARUTI	11,617.35	0.01 ↘	
POLICYBZR	1,409.65	0.30 ↘	

## Research Team

Name	Email ID
<i>Ajit Mishra</i>	<a href="mailto:ajit.mishra@religare.com">ajit.mishra@religare.com</a>
<i>Abhijeet Banerjee</i>	<a href="mailto:abhijeet.banerjee@religare.com">abhijeet.banerjee@religare.com</a>
<i>Gaurav Sharma</i>	<a href="mailto:gauravsharma2@religare.com">gauravsharma2@religare.com</a>
<i>Ashwani Harit</i>	<a href="mailto:ashwani.harit@religare.com">ashwani.harit@religare.com</a>
<i>Divya Parmar</i>	<a href="mailto:divya.parmar@religare.com">divya.parmar@religare.com</a>
<i>Vinay Kalani</i>	<a href="mailto:vinay.kalani1@religare.com">vinay.kalani1@religare.com</a>
<i>Rajan Gupta</i>	<a href="mailto:rajan.gupta1@religare.com">rajan.gupta1@religare.com</a>

## Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

**Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:**

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? <b>[If answer is yes, nature of interest is given below this table]</b>		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: ..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

*No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results"*